Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

@article{Shepherd2000ProspectiveRT,
  title={Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.},
  author={F. Shepherd and J. Dancey and R. Ramlau and K. Mattson and R. Gralla and M. O'Rourke and N. Levitan and L. Gressot and M. Vincent and R. Burkes and S. Coughlin and Y. Kim and J. B{\'e}rille},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2000},
  volume={18 10},
  pages={
          2095-103
        }
}
  • F. Shepherd, J. Dancey, +10 authors J. Bérille
  • Published 2000
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum-based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life. PATIENTS AND METHODS Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer with either measurable or evaluable… Expand
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
TLDR
Second-line docetaxel therapy for advanced NSCLC significantly improves survival with a trend towards less deterioration in QOL compared with BSC, and trends were recorded with QLQ-C30 assessments. Expand
Consolidation Chemotherapy with Docetaxel after Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer: A Preliminary Report
TLDR
Using docetaxel as consolidation chemotherapy in patients with non small cell lung cancer can prolong time to progression of disease and probably patients’ survival without significant adverse effects or negative impact on the quality of life. Expand
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
  • N. Hanna, F. Shepherd, +17 authors P. Bunn
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available. Expand
Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
TLDR
The higher non-haematological toxicity of docetaxel, particularly pulmonary toxicity and diarrhoea, is of concern and warrants further investigation. Expand
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
TLDR
It is concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC. Expand
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials
TLDR
These phase III trials showed that docetaxel provided clinical benefits to patients with non-small cell lung cancer and offers clinically meaningful benefits in the second-line setting. Expand
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
TLDR
Non-inferior survival of gefitinib compared with docetaxel is established, suggesting that gef itinib is a valid treatment for pretreated patients with advanced non-small-cell lung cancer. Expand
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
TLDR
This study demonstrated that this non-platinum doublet (docetaxel+gemcitabine) given on a weekly schedule for advanced NSCLC was well tolerated with efficacy comparable to that reported with platinum-based chemotherapy regimens. Expand
Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
TLDR
The combination regimen of docetaxel-plus-bevacizumab is very active in patients with previously-treated Nsq NSCLC and warrants further research. Expand
Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinum-based chemotherapy.
TLDR
It is confirmed that the docetaxel/vinorelbine schedule has activity in NSCLC patients pretreated with platinum-based therapies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
TLDR
Patients who received docetaxel had a longer time to progression and a greater progression-free survival at 26 weeks and the 1-year survival was significantly greater with D75 than with the control treat... Expand
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
  • F. Fossella, J. Lee, +7 authors B. Glisson
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
TLDR
Docetaxel administered at 100 mg/m2 intravenously every 3 weeks has notable activity against platinum-refractory non-small-cell lung cancer, with a 21% major response rate. Expand
Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
TLDR
Docetaxel is highly active in metastatic breast cancer, even as a third-line treatment, and can be considered as an efficient standard option in second- line treatment. Expand
Management strategies for recurrent non-small cell lung cancer.
Because the benefit of first-line chemotherapy for non-small cell lung cancer (NSCLC) may be marginal, the use of chemotherapy in the second-line setting for the patient who has failed primaryExpand
Docetaxel: meeting the challenge of non-small cell lung cancer management.
TLDR
Response rates of docetaxel were comparable to or better than those seen with previous single-agent chemotherapeutic regimens for advanced NSCLC and even with some combination treatments, with a tolerable adverse event profile. Expand
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
TLDR
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care. Expand
Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
The last decade has seen the introduction of several new chemotherapeutic agents that have activity against non-small cell lung cancer (NSCLC) and produce single-agent response rates of > or = 20% inExpand
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
TLDR
MTA seems to have clinically meaningful activity as a single agent against advanced NSCLC, and nonhematologic toxicity was generally mild or moderate, but 39% of patients developed a grade 3 skin rash. Expand
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
TLDR
MVP is a pragmatic inexpensive chemotherapy regimen that offers useful symptom palliation in patients with advanced NSCLC and merits a 1-2 course therapeutic trial in such patients. Expand
[Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel Cooperative Study Group for Lung Cancer].
TLDR
Docetaxel had an efficacy for non-small cell lung cancer and Hematological adverse reactions included leukopenia and neutropenia of Grade III or more as specified in the Adverse Event Reporting Form proposed by the Japan Society for Cancer Therapy. Expand
...
1
2
...